New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

More Americans are beating cancer than ever, yet many still grapple with treatment's long shadow—especially on their mental ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...

In general, head and neck cancers are treated with surgery, radiation, chemotherapy or a combination. However, head and neck ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

HPV-related throat cancers are rising, but risks can be lowered by avoiding tobacco, limiting alcohol, getting vaccinated, ...

Reduced-dose radiotherapy in head & neck cancer shows similar efficacy to standard dose but with lower toxicity, per findings ...